Cincinnati Children’s has been selected as a full member of the NCI Pediatric Brain Tumor Consortium (PBTC) – the nation’s primary pipeline for bringing new therapies to market for children with brain tumors.
This 10-member consortium works with the National Cancer Institute to rapidly conduct phase I and II clinical evaluations of new medications, biological therapies, treatment delivery technologies and radiation treatment strategies.
Membership in this elite consortium reflects the innovative work of the Brain and Spinal Tumor program at Cincinnati Children’s, led by Maryam Fouladi, MD, MSc, who chairs the consortium. The program – which is part of our Cancer and Blood Diseases Institute – brings together neurosurgery, neuroimaging, pathology, neuropsychology, neurology, endocrinology, oncology, physical medicine and rehabilitation, radiation oncology and other specialties and support staff to help children with brain tumors.
Cincinnati Children’s membership also reflects the efforts of our strong clinical brain tumor team, our leadership in anticancer drug clinical research, and contributions from our Oncology Division clinical management team and our Research Support Core.
With membership in the PBTC, the cancer center at Cincinnati Children’s joins the Children’s Hospital of Philadelphia as the only centers in the country that are members of all the key pediatric cancer drug development consortia.
Those select consortia include the NCI Pediatric Phase I/Pilot Consortium, the New Approaches to Neuroblastoma Therapy (NANT) consortium, the DoD-funded Neurofibromatosis Clinical Consortium, and the Collaborative Ependymoma Research Network.